SecurityUS88167AAE10 / Teva Pharmaceutical Fin Neth 10/01/2026 3.150 Bond
InstitutionBlackrock Debt Strategies Fund, Inc.
Latest Disclosed Value $ 127,115
Blackrock Debt Strategies Fund, Inc. ownership in US88167AAE10 / Teva Pharmaceutical Fin Neth 10/01/2026 3.150 Bond

2025-08-26 - Blackrock Debt Strategies Fund, Inc. has filed a NPORT-P form disclosing ownership of Teva Pharmaceutical Fin Neth 10/01/2026 3.150 Bond (US:US88167AAE10) valued at $127,115 USD as of 2025-06-30. Blackrock Debt Strategies Fund, Inc. had filed a previous NPORT-P on 2025-05-28 disclosing shares of Teva Pharmaceutical Fin Neth 10/01/2026 3.150 Bond valued at of $219,418 USD. This represents a change in value of -42.01 percent during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Teva Pharmaceutical Finance Netherlands III BV DBT US88167AAE10 127 -42.01 0.0221
2025-05-28 2025-03-31 NP Teva Pharmaceutical Finance Netherlands III BV DBT US88167AAE10 219 12.89 0.0390
2025-02-25 2024-12-31 NP Teva Pharmaceutical Finance Netherlands III BV DBT US88167AAE10 195 0.00 0.0354
2024-11-26 2024-09-30 NP Teva Pharmaceutical Finance Netherlands III BV DBT US88167AAE10 195 2.11 0.0369
2024-08-26 2024-06-30 NP Teva Pharmaceutical Finance Netherlands III BV DBT US88167AAE10 191 0.53 0.0377
2024-05-28 2024-03-31 NP Teva Pharmaceutical Finance Netherlands III BV DBT US88167AAE10 189 1.07 0.0374
2024-02-26 2023-12-31 NP Teva Pharmaceutical Finance Netherlands III BV DBT US88167AAE10 188 3.89 0.0370
2023-11-28 2023-09-30 NP Teva Pharmaceutical Finance Netherlands III BV DBT US88167AAE10 181 0.00 0.0360
2023-08-25 2023-06-30 NP Teva Pharmaceutical Finance Netherlands III BV DBT US88167AAE10 181 143.24 0.0362
2023-05-26 2023-03-31 NP Teva Pharmaceutical Finance Netherlands III BV DBT US88167AAE10 75 146.67 0.0150
2023-02-24 2022-12-31 NP Teva Pharmaceutical Finance Netherlands III BV DBT US88167AAE10 30 7.14 0.0062
2022-11-25 2022-09-30 NP Teva Pharmaceutical Finance Netherlands III BV DBT US88167AAE10 29 0.0060
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.